Prospective, multicenter, non-intervention, observational clinical study of anti-angiogenic drugs for advanced renal cancer

Status

Recruiting

Phases

Phase 4

Study type

Observational

Source

ChiCTR

Registry ID

ChiCTR2100044075

Enrollment

Unknown

Registered

2021-03-09

Start date

2021-05-01

Completion date

Unknown

Last updated

2021-07-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

renal carcinoma

Interventions

case series:Nil

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: 1. Aged >= 18 years, male or female; 2. Confirmed advanced or metastatic renal cell carcinoma; 3. The investigators evaluated patients who would benefit from either monotherapy or combination therapy with antiangiogenic agents such as amlotinib; 4. Patients voluntarily participate in the program and sign the informed consent.

Exclusion criteria

Exclusion criteria: 1. Pregnant or lactating women; 2. Concomitant diseases that, in the investigator's judgment, seriously endanger patient safety or affect the completion of the study; 3. Expected survival is less than 3 months.

Design outcomes

Primary

Measure	Time frame
PFS;	—

Countries

China

Contacts

Public ContactShi Benkang

Qilu Hospital of Shandong University

bkshi68@163.com+86 18560083917

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026